Small company mergers - Good for whom?

Nature Biotechnology

Volumn 24, Issue 11, 2006, Pages 1343-1348

  Maybeck, Vanessa ^a   Bains, William ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b Rufus Scientific   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CAPITAL; COMMERCIAL PHENOMENA; DRUG INDUSTRY; DRUG MANUFACTURE; FINANCIAL MANAGEMENT; INVESTMENT; MERGERS AND ACQUISITIONS; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

BIOTECHNOLOGY; GREAT BRITAIN; HEALTH CARE SECTOR; INVESTMENTS; MODELS, ECONOMETRIC; ORGANIZATIONAL AFFILIATION; OWNERSHIP;

EID: 33750888872     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1106-1343     Document Type: Review

References (20)

1. Meeks, G. Disappointing Marriage: A Study of the Gains from Merger Occasional Paper 51, University of Cambridge Department of Applied Economics (Cambridge University Press, Cambridge, UK, 1977).
2. Arbold, R., Grindley, J. & Snart, S. Being acquired should be seen as a legitimate exit strategy for today's biotech entrepreneur. Nat. Biotechnol. 19, 105-111 (1999).
3. Danzon, P.M., Epstein, A. & Nicholson, S. Mergers and acquisitions in the pharmaceutical and biotechnology industries. in NBER Working Paper 10536 (National Bureau of Economic Research, New York, 2004).
4. Anon. Pride comes before a fall (and a bloodbath). Nat. Biotechnol. 20, 1173 (2002).
5. Bassett, P. Paring down the company: the effect of consolidation in the European biotech sector. Nat. Biotechnol. 21, 829-830 (2003).
6. Mitchell, P. UK Bidding war amid merger mania. Nat. Biotechnol. 21, 343-344 (2003).
7. van Brunt, J. M&As were hot in 2005. Signals Magazine (Recombinant Capital, Walnut Creek, California, 24 March 2006; http://www.recap.com).
8. Mitchell, P. UK Industry consolidation is slow despite big merger. Nat. Biotechnol. 21, 215 (2003).
9. Lang, L.H.P. & Stulz, R.M. Tobin's q, corporate diversification, and firm performance. J. Polit. Econ. 102, 1248-1280 (1994).
10. Berger, P.G. & Ofek, E. Diversification's effect on firm value. J. Finan. Econ. 37, 39-65 (1995).
11. Comment, R. & Jarrell, G.A. Corporate focus and stock returns. J. Finan. Econ. 37, 67-87 (1995).
12. Servaes, H. The value of diversification during the conglomerate merger wave. J. Finan. 51, 1201-1225 (1996).
13. John, K. & Ofek, E. Asset sales and increase in focus. J. Finan. Econ. 37, 105-126 (1995).
14. Aggarwal, R.K. & Samwick, A.A. Why do managers diversity their firms? Agency reconsidered. J. Finan. 58, 71-118 (2003).
15. Mansi, S.A. & Reeb, D.M. Corporate diversification: what gets discounted? J. Finan. 57, 2167-2184 (2002).
16. Ruffulo, R. Strategy for re-engineering discovery and development to address R&D productivity. in Drug Discovery Technology Europe (Informa, London, 2005).
17. Jacobs, T. Does biotech M&A benefit investors? Nat. Biotechnol. 22, 1085 (2004).
18. Maybeck, V. Motives and Mergers as Drivers for Change in the Business Model. Thesis, Cambridge Univ. (2005).
19. Colyer, A. Financing as a driver for mergers and acquisitions. Nat. Biotechnol. 17, BE13 (1999).
20. Patterson, D., Cramer, R., Ferguson, A., Clark, R. & Weinburger, L. Neighbourhood behaviour: a useful concept for validation of 'molecular diversity'. J. Med. Chem. 39, 3049-3059 (1996).